NASDAQ · STOK
Stoke Therapeutics, Inc.
$26.35-$0.06 (-0.23%)
Stoke Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.49% below the high.
Loading market information…
NASDAQ · OVID · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Ovid Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 17.68% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Ovid Therapeutics Inc.’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of -$0.08. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Ovid Therapeutics Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy. Beyond these, Ovid is also advancing OV882, a short hairpin RNA (shRNA) gene therapy designed to treat Angelman syndrome, and OV815, targeting neurological disorders connected to the kinesin-family of proteins. To bolster its research and development efforts, Ovid maintains licensing and collaborative agreements with prominent entities such as Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Marinus Pharmaceuticals, Inc. Established in 2014, the company's corporate headquarters are situated in New York, New York.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:10 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 13, 2025 | -$0.140.0% vs estimate | $130.00K+205.88% vs estimate |
|---|
| Q4 2024 | Mar 11, 2025 | -$0.13+18.75% vs estimate | $76.00K-24.0% vs estimate |
|---|
| Q3 2024 | Nov 12, 2024 | -$0.20-5.26% vs estimate | $173.00K-7.73% vs estimate |
|---|
THE ANALYST VIEW
14 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 4 contributors · Median target $6.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$26.35-$0.06 (-0.23%)
Stoke Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.49% below the high.
$16.78-$0.42 (-2.44%)
Ultragenyx Pharmaceutical Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.93% below the high.
$4.22-$0.01 (-0.24%)
Taysha Gene Therapies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.19% below the high.
$9.71-$0.05 (-0.46%)
MeiraGTx Holdings plc’s quoted price sits in the lower half of its reported 52-week range, 36.78% below the high.
$3.63-$0.01 (-0.27%)
Wave Life Sciences Ltd.’s quoted price sits in the lower half of its reported 52-week range, 83.29% below the high.
$28.82-$1.60 (-5.26%)
Neurogene Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.99% below the high.
$2.54-$0.04 (-1.55%)
Rocket Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 53.39% below the high.
$4.56+$0.01 (+0.22%)
Abeona Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 40.39% below the high.
